Appendix 2—table 30. Antihypertensive Cohort (All Regions), Patient Characteristics Pre/Post Match.
| All Observations by Antihypertensive Use: Unmatched | All Observations by Antihypertensive Use: Matched | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All | HTN Non-users | HTN Users | p-value | All | HTN Non-users | HTN Users | p-value | |||||||
| N | % | N | % | N | % | N | % | N | % | N | % | |||
| All Patients | 7,906,603 | 100.0% | 5,805,483 | 73.4% | 2,101,120 | 26.6% | 3,572,002 | 100.0% | 1,786,001 | 50.0% | 1,786,001 | 50.0% | ||
| Age | ||||||||||||||
| ≤20 | 1,840,050 | 23.3% | 1,823,229 | 31.4% | 16,821 | 0.8% | <0.001 | 33,574 | 0.9% | 16,785 | 0.9% | 16,789 | 0.9% | 0.44 |
| 21-40 | 1,446,999 | 18.3% | 1,299,520 | 22.4% | 147,479 | 7.0% | 293,445 | 8.2% | 146,712 | 8.2% | 146,733 | 8.2% | ||
| 41-50 | 925,309 | 11.7% | 685,931 | 11.8% | 239,378 | 11.4% | 463,130 | 13.0% | 231,312 | 13.0% | 231,818 | 13.0% | ||
| 51-60 | 1,250,190 | 15.8% | 759,987 | 13.1% | 490,203 | 23.3% | 870,549 | 24.4% | 434,995 | 24.4% | 435,554 | 24.4% | ||
| 61-70 | 1,181,261 | 14.9% | 626,235 | 10.8% | 555,026 | 26.4% | 918,823 | 25.7% | 459,192 | 25.7% | 459,631 | 25.7% | ||
| 71-80 | 783,775 | 9.9% | 381,957 | 6.6% | 401,818 | 19.1% | 619,578 | 17.3% | 309,898 | 17.4% | 309,680 | 17.3% | ||
| ≥81 | 479,019 | 6.1% | 228,624 | 3.9% | 250,395 | 11.9% | 372,903 | 10.4% | 187,107 | 10.5% | 185,796 | 10.4% | ||
| Gender | ||||||||||||||
| Female | 4,670,960 | 59.1% | 3,402,357 | 58.6% | 1,268,603 | 60.4% | <0.001 | 2,159,365 | 60.5% | 1,079,468 | 60.4% | 1,079,897 | 60.5% | 0.64 |
| Male | 3,235,643 | 40.9% | 2,403,126 | 41.4% | 832,517 | 39.6% | 1,412,637 | 39.5% | 706,533 | 39.6% | 706,104 | 39.5% | ||
| Region | ||||||||||||||
| Midwest | 1,467,802 | 18.6% | 1,065,772 | 18.4% | 402,030 | 19.1% | <0.001 | 694,206 | 19.4% | 347,103 | 19.4% | 347,103 | 19.4% | 1.00 |
| Northeast | 2,152,560 | 27.2% | 1,568,239 | 27.0% | 584,321 | 27.8% | 997,132 | 27.9% | 498,566 | 27.9% | 498,566 | 27.9% | ||
| South | 3,042,604 | 38.5% | 2,240,163 | 38.6% | 802,441 | 38.2% | 1,338,570 | 37.5% | 669,285 | 37.5% | 669,285 | 37.5% | ||
| West | 1,243,637 | 15.7% | 931,309 | 16.0% | 312,328 | 14.9% | 542,094 | 15.2% | 271,047 | 15.2% | 271,047 | 15.2% | ||
| Insurance | ||||||||||||||
| Commercial | 3,938,603 | 49.8% | 3,060,354 | 52.7% | 878,249 | 41.8% | <0.001 | 1,695,516 | 47.5% | 848,106 | 47.5% | 847,410 | 47.4% | 0.80 |
| Dual | 156,497 | 2.0% | 55,827 | 1.0% | 100,670 | 4.8% | 93,467 | 2.6% | 46,774 | 2.6% | 46,693 | 2.6% | ||
| Medicaid | 2,594,500 | 32.8% | 2,091,349 | 36.0% | 503,151 | 23.9% | 812,737 | 22.8% | 406,012 | 22.7% | 406,725 | 22.8% | ||
| Medicare | 1,217,003 | 15.4% | 597,953 | 10.3% | 619,050 | 29.5% | 970,282 | 27.2% | 485,109 | 27.2% | 485,173 | 27.2% | ||
| PCP Visit 2019 | ||||||||||||||
| No | 4,283,697 | 54.2% | 3,531,914 | 60.8% | 751,783 | 35.8% | <0.001 | 1,438,005 | 40.3% | 719,756 | 40.3% | 718,249 | 40.2% | 0.10 |
| Yes | 3,622,906 | 45.8% | 2,273,569 | 39.2% | 1,349,337 | 64.2% | 2,133,997 | 59.7% | 1,066,245 | 59.7% | 1,067,752 | 59.8% | ||
| Continuous Outcomes | ||||||||||||||
| mean | SD | mean | SD | mean | SD | p-value | mean | SD | mean | SD | mean | SD | p-value | |
| CCI | 0.62 | 1.38 | 0.43 | 1.14 | 1.13 | 1.80 | <0.001 | 0.95 | 1.65 | 0.96 | 1.66 | 0.95 | 1.64 | <0.05 |
CCI: Charlson Comorbidity Index; HTN: antihypertensive; PCP: primary care physician; SD: standard deviation.